AARDVARK THERAPEUTICS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-12-20: Study NCT06828861; Company role Lead sponsor; Phase Phase 3; Status Terminated.
- 2024-08-01: Study NCT06126653; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2024-07-23: Study NCT07197034; Company role Lead sponsor; Phase Phase 3; Status Terminated.
- 2022-05-27: Study NCT05153434; Company role Lead sponsor; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-12-20 | NCT06828861 ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial | Lead sponsor | Phase 3 | Terminated | Hyperphagia; Prader-Willi Syndrome | 68 | 2026-05-07 |
| 2024-08-01 | NCT06126653 A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder | Lead sponsor | Phase 2 | Completed | Autism Spectrum Disorder | 5 | 2025-01-13 |
| 2024-07-23 | NCT07197034 The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial | Lead sponsor | Phase 3 | Terminated | Hyperphagia; Prader-Willi Syndrome; Hyperphagia in Prader-Willi Syndrome | 19 | 2026-04-15 |
| 2022-05-27 | NCT05153434 A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome | Lead sponsor | Phase 2 | Completed Results posted | Prader-Willi Syndrome | 19 | 2024-09-24 |
| 2022-03-01 | NCT05215847 Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery | Lead sponsor | Phase 2 | Completed Results posted | Bariatric Surgery; Obesity; Weight Gain | 12 | 2023-02-03 |
| 2021-11-15 | NCT05121441 Study to Evaluate ARD-101 in Adults With Obesity | Lead sponsor | Phase 2 | Completed Results posted | Obesity | 20 | 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |